Consolidation Therapy in Patients With Hematologic Malignancies

Inclusion Criteria

• •1. Ability to provide informed consent.
• •2. Patients at least eighteen (18) years of age with histologically or cytologically proven Multiple Myeloma (MM), Hodgkins Disease (HD), Non-Hodgkins Lymphoma (NHL), Chronic Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL), who have responded to standard, first-line antineoplastic therapy, as defined using standard response criteria for the specific hematologic malignancy (HM), and have no additional potentially curative therapeutic intervention available, will be eligible to participate in this study.
• •3. Expression of one (1) or more of the following TAPAs: SP17, AKAP4, Ropporin, PTTG1 and Span-xb, by either reverse transcriptase polymerase chain reaction (RT-PCR) and/or immunocytochemistry, Western blotting or ELISA, in neoplastic cells and/or blood.
• •4. Presence of measurable or evaluable disease (unless patient has achieved a complete response (CR) following first-line antineoplastic therapy).
• •5. Patients must not have any active infectious process.
• •6. Patients must have a negative test for HIV, Hepatitis A, B, and C.
• •7. Patients must not be receiving active immunosuppressive therapy.
• •8. Patients must have discontinued systemic antineoplastic therapy (including systemic corticosteroids and excluding tyrosine kinase inhibitors for CML) at least four (4) weeks prior to enrollment.
• •9. Patients may not have any known allergy to CYP and/or GM-CSF.
• •10. Patients must be willing to provide at least 250 mL, and up to 500 mL, of whole blood obtained by phlebotomy and/or consent to leukapheresis for DC generation.
• •11. Adequate renal and hepatic function (creatinine ≤ 2.0 mg/dl, bilirubin ≤ 2.0 mg/dl, aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 4X upper limit of normal range).
• •12. Adequate hematologic function (Platelets ≥ 60,000/mm3, lymphocytes ≥ 1,000/mm3, neutrophils ≥ 750/mm3, hemoglobin ≥ 10 g/dl).
• •13. Karnofsky performance status ≥ 70%.
• •14. Expected survival ≥ 6 months.
• •15. Patient Human Leukocyte Antigen (HLA) typing should demonstrate HLA-A\*01, and/or HLA-A\*02, and/or HLA-A\*24 restriction.
• •16. Either a female or male of reproductive capacity wishing to participate in this study must be using, or agree to use, one or more types of birth control during the entire study and for 3 months after completing the study. Birth control methods may include condoms, diaphragms, birth control pills, spermicidal gels or foams, anti-gonadotropin injections, intrauterine devices (IUD), surgical sterilization, or subcutaneous implants. Another choice is for a subject's sexual partner to use one of these birth control methods. Women of reproductive capacity will be required to undergo a urine pregnancy test before completion of the post-screening informed consent process.
• •2. Patients with HM who have undergone myeloablative systemic therapy are ineligible to participate in this study.
• •3. Patients without measurable or evaluable disease (unless patients achieved a complete response (CR) following 1st-line antineoplastic therapy).
• •4. Patients receiving cytotoxic therapy, radiation therapy, immunotherapy or non-topical steroids for HM within four (4) weeks of enrollment, excluding tyrosine kinase inhibitors in patients with CML.
• •5. Active immunosuppressive or cytotoxic therapy (excluding topical steroids) for any other condition.
• •6. Persistent fever (\>24 hours) documented by repeated measurement or active, uncontrolled infection within 4 weeks of enrollment.
• •7. Active ischemic heart disease or history of myocardial infarction within six months.
• •8. Active autoimmune disease, including, but not limited to, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Ankylosing Spondylitis (AS), and Rheumatoid Arthritis (RA).
• •9. Pregnancy or breast feeding.
• •10. Patients with an active second invasive malignancy, other than basal cell carcinoma of the skin.
• •11. Life expectancy of less than 6 months.
• •12. Patients with contraindications to CYP and/or GM-CSF.
• •13. Patients who have received organ transplantations.
• •14. Patients with psychological or geographic conditions that prevent adequate follow-up or compliance with the study protocol.
• •15. Patients diagnosed with primary central nervous system (CNS) or with CNS metastases/involvement, at any time during the disease course, are excluded from the study.
• •16. Patients with HLA-A alleles not belonging to any of the following subtypes: HLA-A\*01, or HLA-A\*02, or HLA-A\*24.